Sandy Sexton, Director, Consumer Marketing, Regeneron Healthcare Solutions
While some people may think eczema is just a rash, they would be wrong. Nearly eight million adults in the U.S. live with eczema, and 1.6 million of them live with uncontrolled moderate-to-severe eczema (atopic dermatitis). The rashes are just the visible signs. As a member of the DUPIXENT® (dupilumab) co-promote team, composed of professionals from Regeneron and Sanofi Genzyme, Sandy Sexton has been dedicated to ensuring education and support is available for patients with moderate-to-severe atopic dermatitis.
DUPIXENT is the first treatment specifically for those living with uncontrolled moderate-to-severe atopic dermatitis, and to get the word out Sandy’s team released a battery of different branded and disease education tactics—all of which involved patients in a meaningful way. They also enlisted the help of Snow Companies to launch two phases of Patient Ambassador® programs.
Phase one consists of a disease awareness program in which participants share their real-life experiences on all disease awareness platforms, including eczemaexposed.com. This group of Patient Ambassadors will continue to educate HCPs, patients, and other stakeholders about the relevance of the issue throughout 2018. The second phase will consist of a branded program, which will launch later this year, to educate the audience about an underlying cause of atopic dermatitis.
So far, numerous patients and caregivers have been overwhelmed by the support and motivation they gained from being involved in Sandy’s team’s programs. “There is nothing like meeting and speaking to others who know from firsthand experience what it’s like,” says Anthony, DUPIXENT MyWay® Ambassador. “It’s an incredible feeling to be validated and vindicated.”
